Rizwana Mohseni

2.0k total citations · 2 hit papers
6 papers, 484 citations indexed

About

Rizwana Mohseni is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Rizwana Mohseni has authored 6 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Hepatology. Recurrent topics in Rizwana Mohseni's work include Liver Disease Diagnosis and Treatment (6 papers), Diet, Metabolism, and Disease (3 papers) and Cancer, Lipids, and Metabolism (2 papers). Rizwana Mohseni is often cited by papers focused on Liver Disease Diagnosis and Treatment (6 papers), Diet, Metabolism, and Disease (3 papers) and Cancer, Lipids, and Metabolism (2 papers). Rizwana Mohseni collaborates with scholars based in United States, Hong Kong and India. Rizwana Mohseni's co-authors include Michelle Lai, Kris V. Kowdley, Kenneth Cusi, Pankaj Patel, Samer Gawrieh, Naga Chalasani, Dhruvanshu Parmar, Nicole Loo, Eugene R. Schiff and Mazen Noureddin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Rizwana Mohseni

5 papers receiving 475 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

2021 261 citations Samer Gawrieh, Mazen Noureddin et al. Hepatology profile →
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

2021 163 citations Rohit Loomba, Rizwana Mohseni et al. Gastroenterology profile →

Peers

Rizwana Mohseni

EPIDE

EDM

MB

HEPAT

CB

Jacqueline Williams Australia

Philippe Delataille France

Francesca Virginia Bruschi Austria

Abraham Younoszai United States

Yasuko Nozaki Japan

Ling Han United States

Jens Christian Nielsen Denmark

Eliza Harting United States

Lampros Chrysavgis Greece

Aliki A. Rasmiena Australia

Jacqueline Williams Australia

Rizwana Mohseni

377 ×0.9

EPIDE

142 ×0.7

EDM

142 ×1.1

MB

111 ×1.0

HEPAT

76 ×0.8

CB

Citations per year, relative to Rizwana Mohseni Rizwana Mohseni (= 1×) peers Jacqueline Williams

Countries citing papers authored by Rizwana Mohseni

Since Specialization

Citations

This map shows the geographic impact of Rizwana Mohseni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rizwana Mohseni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rizwana Mohseni more than expected).

Fields of papers citing papers by Rizwana Mohseni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rizwana Mohseni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rizwana Mohseni. The network helps show where Rizwana Mohseni may publish in the future.

Co-authorship network of co-authors of Rizwana Mohseni

This figure shows the co-authorship network connecting the top 25 collaborators of Rizwana Mohseni. A scholar is included among the top collaborators of Rizwana Mohseni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rizwana Mohseni. Rizwana Mohseni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Neutel, Joel, Ram Gelman, Helena Katchman, et al.. (2023). Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial. SHILAP Revista de lepidopterología. 3(3). 417–425.

2.

Gawrieh, Samer, Mazen Noureddin, Nicole Loo, et al.. (2021). Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial. Hepatology. 74(4). 1809–1824. 261 indexed citations breakdown →

3.

Loomba, Rohit, Rizwana Mohseni, Kathryn Jean Lucas, et al.. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 161(5). 1475–1486. 163 indexed citations breakdown →

4.

Loomba, Rohit, Mary E. Rinella, Stephen A. Harrison, et al.. (2020). Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1). Journal of Hepatology. 73. S53–S54. 3 indexed citations

5.

Loomba, Rohit, et al.. (2020). VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial. Journal of Hepatology. 73. S53–S53. 7 indexed citations

6.

Loomba, Rohit, Joel Neutel, Rizwana Mohseni, et al.. (2019). LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial. Journal of Hepatology. 70(1). e150–e151. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact